English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
 
 
DownloadE-Mail
  Effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: A systematic review

Heidarpour, M., Shafie, D., Aminorroaya, A., Sarrafzadegan, N., Farajzadegan, Z., Nouri, R., et al. (2019). Effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: A systematic review. JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 24: 29. doi:10.4103/jrms.JRMS_955_18.

Item is

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Heidarpour, Maryam, Author
Shafie, Davood, Author
Aminorroaya, Ashraf, Author
Sarrafzadegan, Nizal, Author
Farajzadegan, Ziba, Author
Nouri, Rasool, Author
Najimi, Arash, Author
Dimopoulou, Christina1, Author           
Stalla, Gunter K.1, Author           
Affiliations:
1Max Planck Institute of Psychiatry, Max Planck Society, ou_1607137              

Content

show
hide
Free keywords: -
 Abstract: Background: There is a belief that in patients with acromegaly, first-generation somatostatin analogs (SSAs) might improve cardiovascular (CV) structure and function. However, most published clinical trials involved only a few patients and their results are rather variable. We aimed to conduct a systematic review on available studies on the impact of these drugs on CV parameters. Materials and Methods: A literature search was conducted in MEDLINE (OVID), EMBase, Cochrane, and ISI Web of Science for citations published until April 30 2018 to identify studies on our objective that considered changes in CV parameters. For this search, we established a Boolean search strategy using keywords related to "acromegaly," "Somatostatin analog," and "cardiovascular diseases and parameters." All study types except for case reports or conference abstracts were included. Twenty-four studies (n = 558) fulfilled the inclusion criteria and were selected for final analysis. Results: In 12 studies (n = 350), decrease in heart rate (HR) and in 4 studies (n = 128), decrease in blood pressure (BP) was significant. In 15 studies (n = 320), left ventricular mass index (LVMi) changes were significant. In 9 studies (n = 202), the early diastole to peak velocity flow in late diastole (E/A ratio) was evaluated, and in 5 of them (n = 141), the improvement was significant. Eighteen studies (n = 366) examined changes in left ventricular ejection fraction (LVEF), 5 of which (n = 171) reported that these changes were significant. Decrease of left ventricular end-diastolic diameter was reported in only 2 studies (n = 27). Conclusion: We found that first-generation SSAs have a beneficial effect on cardiac parameters such as HR and LVMi. For other parameters such as LVEF, BP, LV diameter, and E/A ratio, we were not able to draw a firm conclusion.

Details

show
hide
Language(s):
 Dates: 2019
 Publication Status: Published online
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: ISI: 000469802100002
DOI: 10.4103/jrms.JRMS_955_18
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: JOURNAL OF RESEARCH IN MEDICAL SCIENCES
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 24 Sequence Number: 29 Start / End Page: - Identifier: ISSN: 1735-1995